Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.
作者信息
Chong Vui Heng, Chong Pui Lin, Metussin Dhiya, Asli Rosmonaliza, Momin Riamiza Natalie, Mani Babu Ivan, Abdullah Muhammad Syafiq
机构信息
Department of Medicine, PMMPMHAMB Hospital, Tutong, Brunei Darussalam.
Department of Medicine, RIPAS Hospital, Bandar Seri Begawan, Brunei Darussalam.
出版信息
J Med Virol. 2020 Nov;92(11):2322-2324. doi: 10.1002/jmv.26004. Epub 2020 May 22.
Abstract
摘要
相似文献
1
Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.在新冠病毒疾病中，羟氯喹与洛匹那韦/利托那韦联合治疗时的传导异常。
J Med Virol. 2020 Nov;92(11):2322-2324. doi: 10.1002/jmv.26004. Epub 2020 May 22.
2
Skin manifestations associated with the new coronavirus SARS-CoV-2 disease.与新型冠状病毒SARS-CoV-2疾病相关的皮肤表现。
Med Clin (Barc). 2020 Nov 13;155(9):414-415. doi: 10.1016/j.medcli.2020.04.057. Epub 2020 Jul 24.
3
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.羟氯喹和达芦那韦或洛匹那韦治疗 COVID-19 感染的安全性。
J Antimicrob Chemother. 2021 Jan 19;76(2):482-486. doi: 10.1093/jac/dkaa441.
4
In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.洛匹那韦/利托那韦和羟氯喹在通常剂量下可达到的浓度对严重急性呼吸综合征冠状病毒 2 的体外活性。
Korean J Intern Med. 2020 Jul;35(4):782-787. doi: 10.3904/kjim.2020.157. Epub 2020 May 29.
5
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.SARS-CoV-2 全身炎症反应对洛匹那韦和羟氯喹血浆浓度的影响。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01177-20.
6
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.洛匹那韦/利托那韦未能缩短台湾轻症肺炎患者 SARS-CoV-2 脱落持续时间。
J Microbiol Immunol Infect. 2020 Jun;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3.
7
Evaluation of retinotoxicity of COVID-19 treatment: Hydroxychloroquine and lopinavir/ritonavir.新型冠状病毒肺炎治疗药物的视网膜毒性评估：羟氯喹和洛匹那韦/利托那韦
J Med Virol. 2021 Feb;93(2):644-646. doi: 10.1002/jmv.26420. Epub 2020 Sep 28.
8
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.洛匹那韦/利托那韦治疗严重急性呼吸综合征、中东呼吸综合征和 COVID-19：系统评价。
Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8592-8605. doi: 10.26355/eurrev_202008_22659.
9
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
10
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.早期给予利托那韦增强型洛匹那韦可预防重症新型冠状病毒肺炎。
J Infect. 2021 Jan;82(1):159-198. doi: 10.1016/j.jinf.2020.05.039. Epub 2020 May 27.
引用本文的文献
1
Post-COVID-19 health-care utilization: one year after the 2020 first wave in
Brunei Darussalam.新冠疫情后医疗保健的使用情况：文莱达鲁萨兰国 2020 年第一波疫情一年后
Western Pac Surveill Response J. 2023 Jan 18;14(1):1-9. doi: 10.5365/wpsar.2023.14.1.949. eCollection 2023 Jan-Mar.
2
Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.新型冠状病毒肺炎患者与非新型冠状病毒肺炎患者短期口服氯喹和羟氯喹治疗的安全性：一项系统评价
Pharmaceuticals (Basel). 2022 May 21;15(5):634. doi: 10.3390/ph15050634.
3
Prevalence of primary bacterial co-infections among patients with COVID-19 in Brunei Darussalam.文莱达鲁萨兰国 COVID-19 患者原发性细菌合并感染的流行情况。
Western Pac Surveill Response J. 2021 Sep 8;12(3):65-70. doi: 10.5365/wpsar.2021.12.3.856. eCollection 2021 Jul-Sep.
4
Perioperative pain management in COVID-19 patients: Considerations and recommendations by the Saudi Anesthesia Society (SAS) and Saudi Society of Pain Medicine (SSPM).COVID-19患者围手术期疼痛管理：沙特麻醉学会（SAS）和沙特疼痛医学学会（SSPM）的考量与建议
Saudi J Anaesth. 2021 Jan-Mar;15(1):59-69. doi: 10.4103/sja.SJA_765_20. Epub 2021 Jan 5.
5
A case report of a rare cardiac complication in novel coronavirus disease.新型冠状病毒病罕见心脏并发症的病例报告
Eur Heart J Case Rep. 2020 Nov 14;4(6):1-4. doi: 10.1093/ehjcr/ytaa323. eCollection 2020 Dec.
6
A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment.一项关于氯喹和羟氯喹作为单一疗法或联合阿奇霉素治疗 COVID-19 的系统评价和荟萃分析。
Sci Rep. 2020 Dec 17;10(1):22139. doi: 10.1038/s41598-020-77748-x.
7
Imaging in COVID-19-related myocardial injury.COVID-19 相关心肌损伤的影像学表现。
Int J Cardiovasc Imaging. 2021 Apr;37(4):1349-1360. doi: 10.1007/s10554-020-02089-9. Epub 2020 Nov 19.
8
Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.羟氯喹治疗的 SARS-CoV-2 感染患者的长 QT 频率：一项荟萃分析。
Int J Antimicrob Agents. 2020 Dec;56(6):106212. doi: 10.1016/j.ijantimicag.2020.106212. Epub 2020 Oct 24.
9
COVID-19 and the heart: what we have learnt so far.COVID-19 与心脏：迄今我们的了解。
Postgrad Med J. 2021 Oct;97(1152):655-666. doi: 10.1136/postgradmedj-2020-138284. Epub 2020 Sep 17.
10
COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays.COVID-19 药物再利用：计算筛选方法、临床试验和蛋白质相互作用分析的综述。
Med Res Rev. 2021 Jan;41(1):5-28. doi: 10.1002/med.21728. Epub 2020 Aug 30.
本文引用的文献
1
Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India?在印度，新冠大流行是否能成为使用羟氯喹治疗和预防新冠病毒病（COVID-19）的理由？
J Med Virol. 2020 Sep;92(9):1391-1393. doi: 10.1002/jmv.25933. Epub 2020 Jun 3.
2
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.氯喹和羟氯喹在非洲预防或治疗 COVID-19：医疗环境中不适当的超说明书使用需谨慎。
Am J Trop Med Hyg. 2020 Jun;102(6):1184-1188. doi: 10.4269/ajtmh.20-0290.
3
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.羟氯喹在COVID-19危重症患者管理中的应用：循证依据的必要性。
Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15.
4
Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.羟氯喹治疗 COVID-19 患者的病毒学和临床治愈：系统评价和荟萃分析。
J Med Virol. 2020 Jul;92(7):776-785. doi: 10.1002/jmv.25898. Epub 2020 May 3.
5
Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.高血糖、羟氯喹与 COVID-19 大流行。
J Med Virol. 2020 Jul;92(7):770-775. doi: 10.1002/jmv.25887. Epub 2020 Apr 27.
6
Regulators split on antimalarials for COVID-19.监管机构在用于治疗新冠肺炎的抗疟疾药物问题上存在分歧。
Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
7
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
8
Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis.氯喹和羟氯喹与降低心血管风险相关：一项系统评价和荟萃分析。
Drug Des Devel Ther. 2018 Jun 11;12:1685-1695. doi: 10.2147/DDDT.S166893. eCollection 2018.
9
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.氯喹和羟氯喹相关的心脏并发症：文献系统综述。
Drug Saf. 2018 Oct;41(10):919-931. doi: 10.1007/s40264-018-0689-4.
10
Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.预测住院患者QT间期延长风险评分的开发与验证
Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87. doi: 10.1161/CIRCOUTCOMES.113.000152. Epub 2013 May 28.
Zotero 插件